PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Nerandomilast→

Nerandomilast PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1423719-30-5
Molecular formula
C20H25ClN6O2S
Molecular weight
449 g/mol
Drug class
Preferential phosphodiesterase 4B (PDE4B) inhibitorantifibrotic and immunomodulatory small molecule
Mechanism of action
Inhibits PDE4, with at least nine-fold preferential inhibition of PDE4B over PDE4A, PDE4C and PDE4D in vitro. This increases intracellular cAMP and reduces expression of profibrotic growth factors and inflammatory cytokines implicated in pulmonary fibrosis.
Indications / reported uses
  • Treatment of idiopathic pulmonary fibrosis (IPF) in adults
  • Treatment of progressive pulmonary fibrosis (PPF) in adults under the US product indication; it is not an acute bronchodilator or treatment for acute exacerbations

Sources: NLM DailyMed — JASCAYD (nerandomilast), label updated 14 August 2026 · FDA — Jascayd approval for PPF · FDA — Jascayd approval for IPF · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Nerandomilast PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Nerandomilast Permitted Daily Exposure (PDE) report (the Nerandomilast PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Nerandomilast Occupational Exposure Limit (OEL) report (the Nerandomilast OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.